Title: Brain Circuits Involved in the Antidepressant-Like Effects of Ketamine

**Abstract**

There is great interest in studying ketamine given the rapid and sustained behavioral improvement it causes in patients with treatment resistant depression. Much research has focused on the molecular mechanisms of action of ketamine and there is evidence that NMDA receptor antagonism is a necessary component of its activity. Further, such receptors on GABAergic interneurons in the hippocampus are likely to be a primary target for NMDA receptor antagonists.^1^ However, there is a lack of understanding with regard to the contribution of specific brain circuits involved in either its rapid and/or sustained antidepressant-like effects. We used different approaches to examine the role of the ventral hippocampus (vHipp)-medial prefrontal cortex (mPFC) pathway in ketamine's sustained antidepressant-like response in rats, as measured by the use of the forced swim test (FST). These included (1) inactivating pharmacologically the vHipp to mPFC pathway with lidocaine; (2) determining if activation of the pathway using DREADDs would mimic the effect of ketamine in the FST; and (3) activating the pathway using optogenetics to see if this reproduced the effects of ketamine or inactivating it optogenetically to determine if this prevented the effect of ketamine. All three approaches gave results from which it could be concluded that the vHipp to mPFC pathway is both necessary and sufficient for ketamine's antidepressant-like effect. Activation or inhibition of other pathways neither reproduced ketamine's effect nor blocked it.^2^ Because of this, we hypothesized that another way to mimic the antidepressant-like effect of ketamine would be to block or reduce GABAergic transmission in the hippocampus. L-655,708 is a negative allosteric modulator of GABA~A~ receptors and as such, would be expected to block GABAergic activity. In addition, it exhibits selectivity for the α5 subunit of the GABA~A~ receptor with this subunit being localized primarily in the hippocampus.^3^ Systemic administration of this drug produced a sustained (7 days) antidepressant-like effect in the FST. To examine possible rewarding effects of ketamine that could contribute to its abuse potential, self-administration experiments were carried out. Ketamine was self-administered by rats. However, L-655,708 was not. It should be possible, then, to develop novel antidepressants that recapitulate the beneficial effects of ketamine without having abuse-liability.
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